Ono Pharmaceutical Co Ltd represents values of innovation, integrity, and commitment to improving human health. Their corporate philosophy focuses on putting patients first and striving for excellence in research and development. Ono Pharmaceutical aims to contribute to society by developing innovative medicines and therapeutic solutions. With a strong emphasis on compliance and ethical standards, the company actively engages in collaborations and partnerships to accelerate the discovery and development of novel therapies. Through their dedication to advancing healthcare and delivering value to stakeholders, Ono Pharmaceutical Co Ltd has established itself as a leading player in the pharmaceutical industry.

Ono Pharmaceutical Co Ltd is primarily present in Japan.

Ono Pharmaceutical Co Ltd has achieved several significant milestones. Notably, they received approval for Opdivo, an anti-cancer medication, from the U.S. Food and Drug Administration (FDA) in 2014. This approval marked a major breakthrough in cancer treatment, leading to increased survival rates for patients with lung cancer, melanoma, and renal cell carcinoma. Additionally, Ono Pharmaceutical Co Ltd successfully expanded Opdivo's indications for other cancers such as bladder cancer and liver cancer in subsequent years. Furthermore, the company has formed strategic partnerships with international pharmaceutical companies, further strengthening its position in the global market.

Ono Pharmaceutical Co Ltd is a renowned pharmaceutical company based in Japan. Established in 1712, the company has a long-standing history in the healthcare industry. Ono Pharma focuses on the research, development, and manufacturing of innovative drugs and therapeutic solutions. With a strong commitment to improving global health, the company has made significant contributions to the field of oncology, immunology, and central nervous system disorders. Ono Pharma has collaborated with various international partners to expand its reach and enhance its product portfolio. Continuously striving for excellence, Ono Pharmaceutical Co Ltd has emerged as a trusted name in the pharmaceutical sector with its dedication to advancing medical science and improving patient outcomes.

The main competitors of Ono Pharmaceutical Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, and Eisai Co Ltd.

Ono Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Ono Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Ono focuses on the development of prescription drugs in various therapeutic areas, including oncology, immunology, and central nervous system disorders. Ono Pharmaceuticals' business model emphasizes a strong commitment to scientific excellence and collaboration with research institutions and other pharmaceutical companies. By continually investing in cutting-edge research and development, Ono aims to provide effective and safe medications to improve the quality of patients' lives globally.

สัดส่วนราคาต่อกำไรของ Ono Pharmaceutical Co คือ 7.08

KUV ของ Ono Pharmaceutical Co คือ 1.8

AlleAktien คุณภาพสกอร์สำหรับ Ono Pharmaceutical Co คือ 9/10.

Ono Pharmaceutical Co มียอดขายอยู่ที่ 502.67 ล้านล้าน JPY

กำไร Ono Pharmaceutical Co คือ 127.98 ล้านล้าน JPY

Ono Pharmaceutical Co. Ltd is a Japanese pharmaceutical company specializing in the development and distribution of innovative medications for over 70 years. It is headquartered in Osaka and focuses on multiple areas including oncology, immunology, neurology, and infectious diseases. In the field of oncology, Ono has established a leading position in the Asian market and offers a range of innovative treatment options for various types of cancer such as breast, lung, and prostate cancer. Some of their well-known products include Opdivo, an immunotherapy for treating different tumors, and Kyprolis, a medication for multiple myeloma. In the field of immunology, Ono focuses on developing treatments for autoimmune diseases and inflammation. This includes products such as Nivolumab for treating melanoma and renal cancer, Ozanimod for multiple sclerosis, and Etrolizumab for Crohn's disease and ulcerative colitis. Their neurology department encompasses medications for treating conditions like schizophrenia, depression, Parkinson's, and epilepsy. Well-known products in this area include antipsychotics like Olanzapine and Aripiprazole, as well as antiepileptics like Rufinamide and Gabapentin. Ono is also actively involved in developing therapies to combat infectious diseases. Some products in this area include Symbicort for asthma treatment and Dulera, an inhalable corticosteroid for seasonal and perennial allergic rhinitis. Ono's business model is based on continuous research and development of innovative medications that meet the needs of patients and doctors. The company continuously invests in research and development to meet the demands of the fast-paced pharmaceutical industry. Strategic partnerships with other pharmaceutical companies and university research departments also aim to expand their product range. In addition to product development, Ono also invests in improving its manufacturing processes and distribution channels. The company closely collaborates with distribution partners to market its products in Japan and internationally. Ono operates several subsidiary companies, including Ono Pharma USA Inc. and Ono Pharma UK Ltd., to distribute its products worldwide. The company aims to achieve a global reach and constantly expands its international network through partnerships with other companies and academic institutions. Overall, Ono Pharmaceutical Co. Ltd is a leading pharmaceutical company specializing in the development and marketing of innovative medications in various fields. With a strong presence in the Asian market and a growing international reach, Ono remains an important player in the pharmaceutical industry.

Ono Pharmaceutical Co จ่ายเงินปันผล 61 JPY ผ่าน 2 ครั้งในหนภายในหนึ่งปี.

Ono Pharmaceutical Co จ่ายปันผลออก 2 ครั้งต่อปี

ISIN ของ Ono Pharmaceutical Co คือ JP3197600004

WKN ของ Ono Pharmaceutical Co คือ 859650.

ตัวย่อของ Ono Pharmaceutical Co คือ 4528.T

ภายในช่วง 12 เดือนที่ผ่านมา Ono Pharmaceutical Co จ่ายเงินปันผลทั้งหมด 80 JPY นี้เทียบเท่ากับอัตราผลตอบแทนจากเงินปันผลประมาณ 4.24 % สำหรับ 12 เดือนข้างหน้า Ono Pharmaceutical Co คาดว่าจะจ่ายเงินปันผลทั้งหมด 86.14 JPY

อัตราผลตอบแทนเงินปันผลของ Ono Pharmaceutical Co ในปัจจุบันคือ 4.24 %

Ono Pharmaceutical Co จ่ายเงินปันผลทุกไตรมาส การจ่ายเงินปันผลจะเกิดขึ้นในเดือน ตุลาคม, เมษายน, ตุลาคม, เมษายน

Ono Pharmaceutical Co จ่ายเงินปันผลทุกปีในช่วง 23 ปีที่ผ่านมา.

คาดว่าในช่วง 12 เดือนข้างหน้าจะมีการจ่ายเงินปันผลทั้งหมด 86.14 JPY ซึ่งเทียบเท่ากับผลตอบแทนจากเงินปันผลร้อยละ 4.49 %

Ono Pharmaceutical Co ถูกจัดให้อยู่ในภาคส่วน 'สุขภาพ'

เพื่อรับเงินปันผลล่าสุดของ Ono Pharmaceutical Co ในวันที่ 1/12/2567 ที่มูลค่า 40 JPY คุณจะต้องถือหุ้นไว้ในพอร์ตก่อนวันที่เป็น Ex-Tag ในวันที่ 27/9/2567

การจ่ายเงินปันผลครั้งล่าสุดเกิดขึ้นเมื่อวันที่ 1/12/2567

ในปี 2023 บริษัท Ono Pharmaceutical Co ได้จ่ายเงินปันผลเป็นจำนวน 77 JPY

เงินปันผลของ Ono Pharmaceutical Co จะถูกจ่ายใน JPY